Research & Publications †
( † Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)
Stephen G. Ellis, MD, is the Section Head of Invasive/Interventional Cardiology in the Robert and Suzanne Tomsich Department of Cardiovascular Medicine at the Sydell and Arnold Miller Family Heart & Vascular Institute. He also is co-director and co-founder of the Cardiovascular Genebank. His principal clinical interests are complex coronary interventions, novel treatments for inoperable patients, minimally invasive treatments for aortic vale diseases and studies to better understand the basis and predict the occurrence of disease (genomics and proteomics) .
Board-certified in Internal Medicine, Cardiology and Interventional Cardiology, Dr. Ellis is a member of the American Heart Association's Scientific Council on Arteriosclerosis and Scientific Council on Clinical Cardiology .
He also serves on the editorial boards for numerous publications, including the Journal of the American College of Cardiology American Journal of Cardiology, Circulation and the American Heart Journal. Dr. Ellis has authored and co-authored more than 700 papers on interventional cardiology and cardiovascular disease for scientific journals including the New England Journal of Medicine, Circulation, Journal of the American College of Cardiology and American Journal of Cardiology.
He has also served as the principal investigator for numerous national and international clinical studies that have changed the approach to treatment of coronary artery disease, including the RESCUE I trial, GUSTO IIb PTCA study, TAXUS IV and V trials ,the FINESSE trial and the ABSORB III and IV trials.
A graduate of the University of California (at Los Angeles) Medical School, Dr. Ellis completed his internship and residency at Cedars-Sinai Medical Center in Los Angeles and his fellowships at the Brigham and Women's Hospital (Cardiology) in Boston, Stanford University (Cardiology) in Stanford, Calif., and Emory University (Angioplasty) in Atlanta. He has done additional work in Molecular Biology at Penn State University.
Coronary Artery Disease, Stent Restenosis, Total Coronary Occlusions, Angioplasty, Stent-Coronary, Coronary Artery Atherectomy, Coronary Intervention, Drug Eluting Stenting, Heart Valve Disease - Percutaneous Interventions, Stents
Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical education about recent trends. The collaborations are reviewed as part of the Cleveland
Clinic's procedures. The Cleveland Clinic publicly discloses payments to its physicians and scientists for speaking and consulting of $5,000 or more per year, and any equity, royalties, and fiduciary relationships in companies with which they collaborate. The Cleveland Clinic requires its doctors to approve the public disclosures of their scientific collaborations with industry. As of 8/31/2014 the review process regarding Dr. Ellis's disclosure had not been completed. Patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by the Cleveland Clinic. To learn more about the Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.
Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers’ discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.